Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 589 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FDG Clear all
Enrolling by invitation Phase 4 Interventional

Comparing Immune System Suppression to Medication for Unexplained Heart Function and Irregular Heartbeat

NCT06635863
View directory record Official record
Conditions
Ventricular Arrythmia, Non-ischemic Cardiomyopathy, Arrhythmogenic Inflammatory Cardiomyopathy
Interventions
Prednisone 40mg
Drug
Lead sponsor
Roderick Tung
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Phase 4 Interventional Results available

d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis

NCT03549598
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
68Ga-DOTATATE PET/CT, 18FDG PET/CT scan, 13NH3 PET/CT scan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 17, 2026, 11:43 PM EDT
Completed No phase listed Observational

Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement

NCT02608619
View directory record Official record
Conditions
Erdheim-Chester Disease, Langerhans Cell Histiocytosis, Histiocytic Disorders
Interventions
F-choline PET Scan, FDG-PET, biopsy
Radiation · Device · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Not applicable Interventional

Total-Body FDG PET for Radiotherapy Response Assessment in Head and Neck Cancer

NCT05625217
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Total Body PET/CT Imagin
Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

NCT00416455
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Stage I Endometrial Carcinoma, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage IVA Cervical Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, computed tomography, ferumoxtran-10, magnetic resonance imaging, diagnostic lymphadenectomy, lymph node biopsy
Radiation · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
24
States / cities
Los Angeles, California • Sylmar, California • New Britain, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 17, 2026, 11:43 PM EDT
Recruiting Early Phase 1 Interventional

NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease

NCT06453915
View directory record Official record
Conditions
Positron Emission Tomography
Interventions
18F-DPA-714, 18F-FDG
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Completed No phase listed Observational

Verification of Imaging System PCD-1000A

NCT04024748
View directory record Official record
Conditions
Cancer Patients
Interventions
PET/CT imaging
Device
Lead sponsor
Canon Medical Systems, USA
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Henderson, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Phase 1Phase 2 Interventional

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT00662506
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
Cediranib Maleate, Diffusion Tensor Imaging, Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Perfusion Magnetic Resonance Imaging, Positron Emission Tomography, Temozolomide
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 17, 2026, 11:43 PM EDT
Recruiting Phase 3 Interventional

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT05976763
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Zanubrutinib, Rituximab, Patient Observation, Bone Marrow Biopsy, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging, Esophagogastroduodenoscopy, Colonoscopy, Biospecimen Collection, Questionnaire Administration
Drug · Biological · Other + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
60 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
238
States / cities
Little Rock, Arkansas • Beverly Hills, California • Duarte, California + 185 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Recruiting No phase listed Observational

PET/MR for Characterization of Renal Masses (RMs)

NCT06076538
View directory record Official record
Conditions
Renal Tumor, Renal Cell Carcinoma, Renal Tumor, Benign
Interventions
2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Phase 2 Interventional

Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year

NCT03361410
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Grape Powder, Placebo Powder
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 17, 2026, 11:43 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT04293562
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Phase 2 Interventional

An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks

NCT00695305
View directory record Official record
Conditions
Atherosclerosis
Interventions
rilapladib, placebo, 18F Fluorodeoxylucose (FDG)-PET
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Boston, Massachusetts • Brockton, Massachusetts • Haverhill, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 17, 2026, 11:43 PM EDT
Recruiting Phase 1 Interventional

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

NCT07278856
View directory record Official record
Conditions
Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type, Follicular Helper T-Cell Lymphoma, Not Otherwise Specified, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Filgrastim, Fludeoxyglucose F-18, Multigated Acquisition Scan, Pegfilgrastim, Prednisone, Questionnaire Administration, Ruxolitinib Phosphate, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Terminated Phase 1 Interventional

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

NCT05733351
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone, Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Enzalutamide, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Vudalimab
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 17, 2026, 11:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression

NCT00931619
View directory record Official record
Conditions
Epilepsy, Epilepsy, Temporal Lobe, Depression, Depressive Disorder, Major
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Not applicable Interventional

FDG PET/CT in Lung Cancer Staging

NCT02738398
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
FDG PET/CT
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer

NCT00794339
View directory record Official record
Conditions
Cervical Cancer
Interventions
64Cu-ATSM, FDG
Drug
Lead sponsor
American College of Radiology
Other
Eligibility
18 Years and older · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 17, 2026, 11:43 PM EDT
Completed No phase listed Observational Results available

PET/CT Imaging Companion Study To ACTG A5314

NCT02312219
View directory record Official record
Conditions
HIV, Inflammation, Atherosclerosis
Interventions
Folic Acid, Placebo, Low Dose Methotrexate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 17, 2026, 11:43 PM EDT
Terminated Phase 2 Interventional Results available

Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer

NCT00019604
View directory record Official record
Conditions
Liver Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
computed tomography, magnetic resonance imaging, positron emission tomography, radiofrequency ablation, radionuclide imaging, ultrasound imaging, fludeoxyglucose F 18 (FDG-PET), gadopentetate dimeglumine
Procedure · Radiation
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

NCT02338999
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
PET/CT, Pioglitazone, Placebo
Radiation · Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Quantifying Airway Inflammation With Radiologic Tests

NCT00741013
View directory record Official record
Conditions
Lung Inflammation
Interventions
placebo pill and placebo IV, Lovastatin pill and placebo IV, placebo pill and recombinant human activated protein C IV, Endotoxin
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years to 44 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Phase 2 Interventional Results available

Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer

NCT03416153
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Carboplatin, Radiation Therapy, Paclitaxel
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Terminated Not applicable Interventional

Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung & Liver Lesions and Assessment of Tumor Glycolysis

NCT01052766
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
PET/CT and BH PET/CT
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 17, 2026, 11:43 PM EDT